182 related articles for article (PubMed ID: 11375113)
1. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes.
Kino T; Chrousos GP
J Endocrinol; 2001 Jun; 169(3):437-45. PubMed ID: 11375113
[TBL] [Abstract][Full Text] [Related]
2. Familial/sporadic glucocorticoid resistance syndrome and hypertension.
Kino T; Vottero A; Charmandari E; Chrousos GP
Ann N Y Acad Sci; 2002 Sep; 970():101-11. PubMed ID: 12381545
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid and mineralocorticoid receptors and associated diseases.
Kino T; Chrousos GP
Essays Biochem; 2004; 40():137-55. PubMed ID: 15242344
[TBL] [Abstract][Full Text] [Related]
4. Tissue glucocorticoid resistance/hypersensitivity syndromes.
Kino T; De Martino MU; Charmandari E; Mirani M; Chrousos GP
J Steroid Biochem Mol Biol; 2003 Jun; 85(2-5):457-67. PubMed ID: 12943736
[TBL] [Abstract][Full Text] [Related]
5. A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators.
Vottero A; Kino T; Combe H; Lecomte P; Chrousos GP
J Clin Endocrinol Metab; 2002 Jun; 87(6):2658-67. PubMed ID: 12050230
[TBL] [Abstract][Full Text] [Related]
6. The N-terminal domain of the mineralocorticoid receptor modulates both mineralocorticoid receptor- and glucocorticoid receptor-mediated transactivation from Na/K ATPase beta1 target gene promoter.
Derfoul A; Robertson NM; Hall DJ; Litwack G
Endocrine; 2000 Dec; 13(3):287-95. PubMed ID: 11216640
[TBL] [Abstract][Full Text] [Related]
7. Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking.
Kino T; Stauber RH; Resau JH; Pavlakis GN; Chrousos GP
J Clin Endocrinol Metab; 2001 Nov; 86(11):5600-8. PubMed ID: 11701741
[TBL] [Abstract][Full Text] [Related]
8. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity.
Charmandari E; Raji A; Kino T; Ichijo T; Tiulpakov A; Zachman K; Chrousos GP
J Clin Endocrinol Metab; 2005 Jun; 90(6):3696-705. PubMed ID: 15769988
[TBL] [Abstract][Full Text] [Related]
9. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene.
Karl M; Lamberts SW; Detera-Wadleigh SD; Encio IJ; Stratakis CA; Hurley DM; Accili D; Chrousos GP
J Clin Endocrinol Metab; 1993 Mar; 76(3):683-9. PubMed ID: 8445027
[TBL] [Abstract][Full Text] [Related]
10. Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS.
Trapp T; Rupprecht R; Castrén M; Reul JM; Holsboer F
Neuron; 1994 Dec; 13(6):1457-62. PubMed ID: 7993637
[TBL] [Abstract][Full Text] [Related]
11. Familial/sporadic glucocorticoid resistance: clinical phenotype and molecular mechanisms.
Charmandari E; Kino T; Chrousos GP
Ann N Y Acad Sci; 2004 Jun; 1024():168-81. PubMed ID: 15265781
[TBL] [Abstract][Full Text] [Related]
12. A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1.
Tajima T; Kitagawa H; Yokoya S; Tachibana K; Adachi M; Nakae J; Suwa S; Katoh S; Fujieda K
J Clin Endocrinol Metab; 2000 Dec; 85(12):4690-4. PubMed ID: 11134129
[TBL] [Abstract][Full Text] [Related]
13. Characterization of two novel mutations in the glucocorticoid receptor gene in patients with primary cortisol resistance.
Ruiz M; Lind U; Gåfvels M; Eggertsen G; Carlstedt-Duke J; Nilsson L; Holtmann M; Stierna P; Wikström AC; Werner S
Clin Endocrinol (Oxf); 2001 Sep; 55(3):363-71. PubMed ID: 11589680
[TBL] [Abstract][Full Text] [Related]
14. Modulation of HIV-1 virulence via the host glucocorticoid receptor: towards further understanding the molecular mechanisms of HIV-1 pathogenesis.
Hapgood JP; Tomasicchio M
Arch Virol; 2010 Jul; 155(7):1009-19. PubMed ID: 20446002
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance.
Funder JW
Annu Rev Med; 1997; 48():231-40. PubMed ID: 9046958
[TBL] [Abstract][Full Text] [Related]
16. Multiple aspects of mineralocorticoid selectivity.
Farman N; Rafestin-Oblin ME
Am J Physiol Renal Physiol; 2001 Feb; 280(2):F181-92. PubMed ID: 11208593
[TBL] [Abstract][Full Text] [Related]
17. Familial glucocorticoid receptor haploinsufficiency by non-sense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess.
Bouligand J; Delemer B; Hecart AC; Meduri G; Viengchareun S; Amazit L; Trabado S; Fève B; Guiochon-Mantel A; Young J; Lombès M
PLoS One; 2010 Oct; 5(10):e13563. PubMed ID: 21042587
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticosteroid resistance in humans. Elucidation of the molecular mechanisms and implications for pathophysiology.
Stratakis CA; Karl M; Schulte HM; Chrousos GP
Ann N Y Acad Sci; 1994 Nov; 746():362-74; discussion 374-6. PubMed ID: 7825890
[TBL] [Abstract][Full Text] [Related]
19. Familial glucocorticoid resistance caused by a novel frameshift glucocorticoid receptor mutation.
Trebble P; Matthews L; Blaikley J; Wayte AW; Black GC; Wilton A; Ray DW
J Clin Endocrinol Metab; 2010 Dec; 95(12):E490-9. PubMed ID: 20861124
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators.
Kino T; Gragerov A; Slobodskaya O; Tsopanomichalou M; Chrousos GP; Pavlakis GN
J Virol; 2002 Oct; 76(19):9724-34. PubMed ID: 12208951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
